Lung cancers

Carcinomas of the lung click to access explanations in the original CAP template

There is further reference to , IASLC atlas for ALK1 and ROS1 (2e, 2016) and updated 2018 CAP-IASLC-AMP guidelines for selection of tyrosine kinase inhibitors for NSCLC patients .

Microscopic descriptions:

- Tumor histology and immunohistochemical studies:

- Histologic type: specify % individual components/patterns if applicable
+ Histologic grade:
- Spread through air spaces (STAS):
- Visceral pleura invasion:
- Lymphatic and / or Vascular Invasion:
- Tumor extension:	Not applicable Adjacent structures present but not involved Adjacent lobe of lung Parietal pleura Chest wall, fibroadipose tissue Chest wall, skeletal muscle Chest wall, rib(s) Main bronchus (up to but not including the carina) Associated with atelectasis or obstructive pneumonitis extending to the hilar regions, involving either part of or all of the entire lung Hilar soft tissues Phrenic nerve Parietal pericardium Visceral pericardium (epicardium) Azygos vein Cervical nerve roots Thoracic nerve roots Brachial plexus (trunks, divisions, cords, or terminal nerves) Stellate ganglion Diaphragm Heart Great vessels (aorta, superior / inferior vena cava, intrapericardial pulmonary arteries / veins) Supra-aortic arteries Brachiocephalic vein Subclavian vessels Thymus Trachea Carina Recurrent laryngeal nerve Vagus nerve Esophagus Vertebral body Lamina Spinal canal Other (specify): Cannot be assessed (explain):
- Treatment effect:

- Bronchial margin:	Not applicable Cannot be assessed Uninvolved by invasive carcinoma Uninvolved by carcinoma in situ Involved by invasive carcinoma Involved by carcinoma in situ
- Vascular margin:
- Parenchymal margin:	Not applicable Cannot be assessed Uninvolved by invasive carcinoma Uninvolved by lepidic component of invasive adenocarcinoma Uninvolved by adenocarcinoma in situ Involved by invasive carcinoma Involved by lepidic component of invasive adenocarcinoma Involved by adenocarcinoma in situ
- Other tissue margin(s):

Regional lymph nodes: Specify the locations of involved lymph nodes.

- Number of regional lymph nodes examined:
- Number of lymph nodes involved:
+ Extranodal extension:

Distant Metastasis: Not applicable Not identified Single extrathoracic metastasis in one organ (includes a single non-regional lymph node) (specify): Separate tumor nodule(s) in contralateral lobe (specify): Pleural nodules (specify): Pericardial nodules (specify): Malignant pleural effusion (specify): Malignant pericardial effusion (specify): Multiple extrathoracic metastases in a single organ (specify): Multiple extrathoracic metastasis in multiple organs (specify): Other (specify): Cannot be determined:

Pathologic Stage Classification (AJCC 9e):

- TNM Descriptors:	m (multiple primary tumors) r (recurrent) y (post treatment)
- Primary tumor (pT):
- Regional lymph nodes (pN):
- Distant metastasis (pM):

+ Additional pathologic findings:

Atypical adenomatous hyperplasia Tumorlets: Squamous dysplasia Diffuse neuroendocrine hyperplasia Biopsy site changes Granulomatous inflammation, necrotizing Granulomatous inflammation, non-necrotizing Post-obstructive changes Fibrosis (specify pattern if discernable): Emphysema

- Other (specify):

- Additional notes: